The White House said on Tuesday, November 17, that it has pulled the nomination of Dr. Heidi Overton to lead the Food and Drug Administration, one day before the Senate health committee was scheduled to vote on whether to send her to the full Senate, amid growing indications she did not have the votes needed to win confirmation. Overton "lacks the support on the Hill to move forward with her confirmation," a senior administration official told Axios, which first reported the decision late on Tuesday. The withdrawal leaves the FDA — the agency that regulates drugs, vaccines, medical devices and much of the food supply — under acting leadership for a seventh month, with no successor named and Republicans racing to confirm nominees before they hand over power to Senate Democrats in January.

Source: Associated Press via KXL

The Senate math that decided it

To win confirmation, Overton would have needed the votes of all 12 Republicans on the Senate Health, Education, Labor and Pensions (HELP) Committee, where Democrats hold 11 seats; losing a single Republican would have sunk the nomination if every Democrat voted no, and no Democrats were expected to back her. The committee vote had been scheduled for Wednesday morning, November 18. Hours before the withdrawal, Senators Susan Collins of Maine and Lisa Murkowski of Alaska had not said how they would vote, CBS News reported. Committee chairman Bill Cassidy, a Louisiana Republican and a doctor, said earlier on Tuesday that he remained undecided about Overton ahead of the vote.

12–11Republican–Democrat split on the HELP Committee; Overton needed all 12 Republicans
Aug. 19Date Overton was nominated to lead the FDA
Sept. 24Date of her Senate confirmation hearing
~7 monthsTime the FDA has now gone without a permanent, confirmed leader

Vaccines: the chairman's "almost disqualifying" objection

Overton, a physician and White House domestic policy adviser who serves as deputy director of the Domestic Policy Council, has spent most of her professional career working directly for President Donald Trump or conservative groups aligned with his agenda, the Associated Press reported. Her nomination in August was seen as a move to bring a stabilising Trump loyalist to the FDA following a tumultuous year under Trump's first FDA commissioner, Dr. Marty Makary, who resigned in May. But Overton faced bipartisan questions about her willingness to break from Trump, particularly on vaccines. Cassidy had previously called her support for Trump's plan to break up combination vaccines — including the measles, mumps and rubella (MMR) shot — "almost disqualifying," and at her September 24 hearing he pressed her on scientific independence and her willingness to disagree with Trump and Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic. Overton told the panel the MMR vaccine and every other vaccine on the U.S. market are safe and effective, and said she would give the president her best advice and follow the legal requirements of the commissioner's role; she declined to say explicitly that Trump was wrong about the MMR vaccine's safety, AP reported.

Cassidy's late-night reversal: "she would have had the votes"

Late on Tuesday night, Cassidy suggested he had in fact been prepared to back Overton, and that her nomination was derailed by disagreements over abortion, not vaccines. "I believe she would have had the votes to pass out of committee and pass the full Senate," Cassidy stated in a posting on X. He said anti-abortion Republicans had sought commitments on "life issues" from the White House, but "the Administration withdrew Dr. Overton rather than make such commitments." Cassidy has repeatedly tried to win commitments on upholding vaccine standards by threatening to withhold his vote, though he ultimately voted for each health nominee who came before his committee; he lost his June primary and has weeks left in his term, AP reported. The two accounts — the White House's stated lack of votes and Cassidy's claim the votes were there — have not been reconciled, and the administration has not commented on Cassidy's version beyond the withdrawal itself.

Two explanations, on the record

White House via AP and Axios: the nomination was pulled amid growing indications Overton did not have the votes, with a senior official saying she "lacks the support on the Hill." Sen. Bill Cassidy on X, late Tuesday: "I believe she would have had the votes to pass out of committee and pass the full Senate," blaming a White House refusal to make "life issues" commitments sought by anti-abortion Republicans.

The abortion pill, vaping and the questions that piled up

The FDA is currently conducting a safety review of the abortion pill mifepristone at Trump's request, which could reinstate restrictions on the drug's use, including a requirement for in-person prescribing; the agency has promised a report on its safety findings by March. That review ran through Overton's hearing: Sen. Josh Hawley of Missouri questioned whether her hearing statements on mifepristone matched what the administration was arguing in ongoing litigation, Government Executive reported; Sen. Patty Murray of Washington asked about a 2023 article in which Overton called mifepristone dangerous to women, and Overton answered that the drug "has met the safety and efficacy determinations of the FDA" and that she did not want to prejudge the review, according to Roll Call reporting. Cassidy told her he wanted the next commissioner to require an in-person ultrasound before mifepristone is dispensed and to have physicians report adverse events tied to the drug, while Murkowski warned that requiring in-person dispensing would put a rural state such as Alaska in a difficult position. The anti-abortion group Susan B. Anthony Pro-Life America urged senators to delay her confirmation, CBS News reported. Collins, meanwhile, raised concerns including Overton's approach to flavoured e-cigarettes, after the FDA recently authorised the first fruit-flavoured e-cigarettes for adult smokers looking to quit; CBS reported Overton helped carry out Trump's pro-vaping policies on the Domestic Policy Council, and that Makary has said tobacco companies pressured him to approve fruit-flavoured vapes and that he refused.

Opposition from inside the president's own health movement

Opposition also came from influential figures in the Make America Healthy Again (MAHA) movement. Earlier this month, Calley Means told Joe Rogan that White House aides, including Overton, worked within the administration to advance a Supreme Court decision blocking thousands of lawsuits over the weedkiller glyphosate. "There is a very concentrated group in the Trump administration that are antagonistic to what people voted for," Means said. Means, a former Kennedy aide who recently left the government, told CBS News Overton was "the biggest block to MAHA policies I encountered in the government." Against that, White House spokesperson Kush Desai said in August that Overton had been integral to keeping the administration's policies "grounded in Gold Standard Science," Kennedy praised her "exceptional judgment" after the nomination, and two former FDA commissioners endorsed her, CBS News and Government Executive reported. Overton trained as a general surgery resident at Johns Hopkins, is board-certified in public health and general preventive medicine, holds a Ph.D. in clinical investigation from the Johns Hopkins Bloomberg School of Public Health, served as a White House fellow from 2019 to 2020 and was chief policy officer at the America First Policy Institute before rejoining the administration.

An agency already running on acting leadership

The FDA is currently being led on an acting basis by Kyle Diamantas, an attorney and friend of Donald Trump Jr. who was elevated to the post in May after serving as the agency's top food official; under federal rules, acting officials are limited to about seven months leading a federal agency, AP reported. The FDA under Makary was marked by scientific disputes, leadership changes and reports of low morale and internal dysfunction; the agency has lost about 20% of its employees to layoffs, buyouts, retirements or resignations since Trump took office. Overton is not the first health nomination to collapse: Trump's first nominee for the Centers for Disease Control and Prevention, Dr. David Weldon, was replaced because it was unclear he had enough Republican support, and two surgeon general nominees, including Dr. Casey Means — Calley Means' sister — were also pulled after pushback from Senate Republicans and most Democrats.

Why this matters for households, including diaspora families

The commissioner who eventually takes this job will steer the FDA through new vaccine recommendations, revamped rare-disease drug reviews and the mifepristone safety review, Bloomberg Government and Medical Economics reported — decisions that reach every pharmacy, grocery shelf and clinic in the country. For Awaaz Punjab's U.S. readers, many of them immigrant families who follow vaccine schedules for school-age children and rely on the FDA's food and medicine safety calls, an agency led by an acting chief approaching the federal time limit is not an abstract Washington story: approvals, safety warnings and vaccine guidance all carry the acting leadership's signature until the Senate confirms a permanent commissioner.

What happens next

It was not immediately clear when, or if, the White House might put forward another nominee, AP reported. CBS News reported the White House has talked with possible replacements, including candidates who could serve as acting commissioner without Senate confirmation, and that Sen. Roger Marshall of Kansas, a doctor, is reportedly considering the job — a report the White House has not confirmed. What is fixed is the calendar: Republicans are racing to confirm Trump's pending nominees before handing over power to Senate Democrats in January, following the November 3 midterm elections, and Diamantas's acting tenure is approaching the roughly seven-month federal limit AP cited. Awaaz Punjab will follow the naming of any successor and the HELP Committee's next vote.